Evidence map›Paper›PMID 23471131›Full record

Trial reportClinical journal of the American Society of Nephrology : CJASN2013

Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD.

Tamara Isakova, Allison Barchi-Chung, Gwen Enfield, Kelsey Smith, Gabriella Vargas, Jessica Houston, Huiliang Xie, Patricia Wahl, Eva Schiavenato, Austin Dosch and 7 more

Abstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 6 pooled it
9.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 6 syntheses or guidelines pooled it, 147 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2019
    Trial
  9. Trial
  10. Trial
  11. Phosphorus Additives and Albuminuria in Early Stages of CKD: A Randomized Controlled Trial.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2017
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Review
  19. Review
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Tamara IsakovaDivision of Nephrology and Hypertension, Department of Medicine, Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA.
Allison Barchi-Chung
Gwen Enfield
Kelsey Smith
Gabriella Vargas
Jessica Houston
Huiliang Xie
Patricia Wahl
Eva Schiavenato
Austin Dosch
Orlando M Gutiérrez
Jorge Diego
Oliver Lenz
Gabriel Contreras
Armando Mendez
Rory B Weiner
Myles Wolf
Hypertension Institute · USClinical Research Management · USMassachusetts General Hospital · USUniversity of Alabama at Birmingham · USUniversity of Miami · US

Funding

Miami Clinical and Translational Science InstituteUL1TR000460 · NCATS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SACCO, RALPH L. · 2012 to 2016
$16.9M
FGF23 and Cardiovascular Disease in CKDR01DK081374 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI WOLF, MYLES S · 2008 to 2016
$4.2M
Role of FGF-23 in Mineral Metabolism Across the Spectum of Chronic Kidney DiseaseR01DK076116 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI WOLF, MYLES S · 2007 to 2016
$2.9M
Calcium Handling and Secondary Hyperparathyroidism in Chronic Kidney DiseaseK23DK087858 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI ISAKOVA, TAMARA · 2010 to 2014
$845k
Mentored Patient Oriented Research in Mineral MetabolismK24DK093723 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI WOLF, MYLES S · 2012 to 2016
$803k
NCATS NIH HHS 1UL1TR000460NCATS NIH HHS UL1 TR000460NIDDK NIH HHS K23 DK087858NIDDK NIH HHS K23DK087858NIDDK NIH HHS K24 DK093723NIDDK NIH HHS R01 DK076116NIDDK NIH HHS R01DK076116NIDDK NIH HHS R01 DK081374NIDDK NIH HHS R01DK081374
6 · The paper itself

Abstract

backgroundElevated levels of fibroblast growth factor 23 (FGF23) are associated with increased risk of adverse outcomes in patients with CKD. Reducing dietary phosphate intake or absorption may decrease FGF23 levels, but data on the combined effects of dietary phosphate restriction and phosphate binders in CKD are limited. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this 2×2 factorial, single-blinded, placebo-controlled, 3-month study, conducted between July 2009 and March 2012, 39 patients with CKD stages 3 or 4 and normal serum phosphate levels were randomly assigned to one of four groups: ad libitum diet plus lanthanum carbonate (LC) placebo (n=10), 900-mg phosphate diet plus LC placebo (n=10), ad libitum diet plus LC (n=11), or 900-mg phosphate diet plus LC (n=8). The dose of LC was 1000 mg three times daily with meals. Dietary restriction was accomplished with outpatient counseling. The primary end point was change in FGF23 levels from baseline.

resultsCompared with ad libitum diet, the 900-mg phosphate diet did not significantly reduce FGF23 levels (diet × time interaction, P=0.05). Compared with placebo, LC alone also did not significantly reduce FGF23 levels (LC × time interaction, P=0.21). However, the dual intervention significantly decreased FGF23 levels throughout the study period (diet × LC × time interaction, P=0.02), resulting in a 35% (95% confidence interval, 8%-62%) reduction by study end.

conclusionThe combination of LC plus counseling for a phosphate-restricted diet decreased FGF23 levels in patients with CKD stages 3-4 and normal serum phosphate levels.

Indexed as

AdultAgedChelating AgentsCombined Modality TherapyDown-RegulationFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsFloridaHumansLanthanumLeast-Squares AnalysisMaleMiddle AgedPhosphatesPhosphorus, DietaryChelating AgentsFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsLanthanumlanthanum carbonatePhosphatesPhosphorus, Dietary

Identifiers

PMID23471131
PMCPMC3675851
OpenAlexW2137069121

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.